Biosight Ltd.

biosight is a biopharmaceutical company focused on research and development of innovative cancer targeted pro-drugs. biosight has developed the s2dot technology and pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments. the company’s pipeline is led by astarabine, a pro-drug of the chemotherapy drug cytarabine (arac). a carrier structure of astarabine gives the pro-drug significant advantages over the free chemotherapy molecule, enabling malignant cell specific targeting. astarabine is currently at a phase i/iia clinical study for treatment of leukemia.